Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).
Lim SH, Lee KW, Kim JJ, Im HS, Kim IH, Han HS, Koo DH, Cho JH, Maeng CH, Lee MY, Lee HJ, Kim JH, Park SG, Jung JY, Shin SH, Kim KH, Kim H, Oh SY, Kang M, Jung M, Rha SY. Lim SH, et al. Among authors: cho jh. BMC Cancer. 2024 Feb 23;24(1):252. doi: 10.1186/s12885-024-11972-w. BMC Cancer. 2024. PMID: 38395832 Free PMC article.
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea.
Kim HK, Lee SH, Kim YJ, Park SE, Lee HS, Lim SW, Cho JH, Kim JY, Ahn JS, Im YH, Yu JH, Park YH. Kim HK, et al. Among authors: cho jh. BMC Cancer. 2019 Jan 17;19(1):84. doi: 10.1186/s12885-018-5258-9. BMC Cancer. 2019. PMID: 30654765 Free PMC article.
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
Kim H, Kim DW, Kim M, Lee Y, Ahn HK, Cho JH, Kim IH, Lee YG, Shin SH, Park SE, Jung J, Kang EJ, Ahn MJ. Kim H, et al. Among authors: cho jh. Cancer. 2022 Feb 15;128(4):778-787. doi: 10.1002/cncr.33984. Epub 2021 Oct 27. Cancer. 2022. PMID: 34705268 Free PMC article.
Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18.
Choi DH, Kim M, Kim YS, Park KU, Cho JH, Kim H, Lee KH, Ahn H, Kim IH, Lee KH, Lee GW, Yi SY, Ahn BC, Lee MY, Jung HA, Park S, Sun JM, Ahn JS, Lee SH, Ahn MJ. Choi DH, et al. Among authors: cho jh. JTO Clin Res Rep. 2024 Oct 16;5(12):100734. doi: 10.1016/j.jtocrr.2024.100734. eCollection 2024 Dec. JTO Clin Res Rep. 2024. PMID: 39619275 Free PMC article.
4,269 results